Meforal

Metformin Hydrochloride, the active ingredient in Meforal, is a biguanide presented as an oral tablet for oral use. It is employed to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Meforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches that meet EU regulatory standards and providing reliable logistics for global distribution. The company follows stringent quality control and provides regulatory documentation to support import and clinical use.

Meforal (metformin hydrochloride) is an oral antidiabetic agent indicated for conditions involving abnormal glucose metabolism.

Type 2 diabetes mellitus: reduces fasting and post‑prandial blood glucose levels, improving overall glycemic control and reducing long‑term complications. Impaired glucose tolerance (prediabetes): enhances insulin sensitivity and lowers hepatic glucose output, helping to delay or prevent progression to type 2 diabetes in at‑risk individuals.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Loss of appetite. - Mild headache.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal accumulation of lactate. - Vitamin B12 deficiency: may develop with long‑term therapy. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction or unexplained hypoglycemia when combined with other glucose‑lowering agents.

Precautions: - Renal function: assess creatinine clearance before initiating therapy and monitor periodically. - Hepatic function: avoid use in patients with significant liver disease. - Cardiovascular status: use cautiously in patients with congestive heart failure. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Pregnancy and lactation: safety not established; evaluate risk‑benefit with a healthcare professional. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Interactions: Major Interactions (Avoid): - Iodinated contrast agents: may cause acute renal failure; discontinue metformin before and after imaging. - Cimetidine: can increase metformin plasma concentrations, raising lactic acidosis risk. - Excessive alcohol: enhances risk of lactic acidosis. - Renal‑toxic drugs (e.g., aminoglycosides, NSAIDs): may impair metformin clearance.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Thiazide diuretics: can increase blood glucose, requiring dose adjustment. - Corticosteroids: may reduce metformin efficacy. - ACE inhibitors: monitor renal function and electrolytes during combined therapy.